By IDSE News Staff
Patients with COVID-19 are less likely to develop long COVID if they receive early treatment with convalescent plasma containing antibodies against SARS-CoV-2 (mBio 2023;14[5]:e0061823).
The new research from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health is a follow-up to a 2021 clinical trial that showed convalescent plasma was an effective and safe option as an early outpatient treatment for COVID-19 (